



**NEPHRO CARE INDIA LIMITED**

CIN: L85100WB2014PLC202429

Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,  
Bidhan Nagar, Sai Complex, North 24 Parganas, Kolkata – 700106.

Web: <https://www.nephrocareindia.com/>

[cs@nephrocareindia.com](mailto:cs@nephrocareindia.com) | Mobile No. 9004551166

**Date: 28/05/2025**

**To,**  
**The Manager - Listing Department**  
**National Stock Exchange of India Limited,**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051

**Symbol - NEPHROCARE**

**Sub: Outcome of Board Meeting dated 28<sup>th</sup> May 2025**

**Ref: Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

Pursuant to the provision of Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”) this is to inform you that the Board of Directors of the Company at its meeting duly held today Wednesday, 28<sup>th</sup> May, 2025, (commenced at 02:00 P.M and concluded at 04:45 P.M) through Video Conferencing (Audio Visual Means) *inter alia*, approved and adopted the following;

- 1) The Audited Standalone Financial Results for the half year and year ended 31<sup>st</sup> March 2025 along with the Statement of Assets & Liabilities and Cash Flow Statement for financial year ended 31<sup>st</sup> March 2025;
- 2) Independent Auditors’ Report on Financial Results for the half and year ended 31<sup>st</sup> March, 2025, duly issued by the statutory auditor of the Company;
- 3) Declaration that the report of Auditor is with unmodified opinion with respect to Audited Financial Results for the half and year ended 31<sup>st</sup> March, 2025.

***OTHER MATTERS***

- 4) Noting of Internal Audit Report provided by the Internal Auditor of the Company, M/s M. Dutta & Associates.
- 5) Authorisation to Dr. Pratim Sengupta, Managing Director, Mr. Sougata Sengupta, Company Secretary, and Mr. Buddha Das, Center in charge Business development of the Company, severally, to do all such acts, deeds, and things as may be necessary and/or incidental for the



**NEPHRO CARE INDIA LIMITED**

CIN: L85100WB2014PLC202429

Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,  
Bidhan Nagar, Sai Complex, North 24 Parganas, Kolkata – 700106.

Web: <https://www.nephrocareindia.com/>

[cs@nephrocareindia.com](mailto:cs@nephrocareindia.com) | Mobile No. 9004551166

implementation and execution of the Bandra Project, including submission, execution, signing of other documents, as may be required from time to time.

- 6) Noting of Related Party Transaction(s) for the half year ended 31<sup>st</sup> March 2025
- 7) Opening of Bank Account with HDFC Bank in Mumbai for Bandra Project.
- 8) Authorisation to Dr. Pratim Sengupta, Managing Director, of the Company to execute, enter and do all the acts, deed and things as may be required for the Ranchi Nephrology Clinic Business Collaboration Agreement.
- 9) Formation of Sub Committee of Board named as Business Alliance & Growth Committee.

The Board meeting commenced at 02:00 P.M and concluded at 4:45 P.M (IST).

The above announcements are also being made available on the website of the Company at [www.nephrocareindia.com](http://www.nephrocareindia.com).

Thanking you,

Yours Faithfully,

**For Nephro Care India Limited**

**Sougata Sengupta**  
**Company Secretary & Compliance Officer**